🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

George R. Blumenschein

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0002-9606-8194
Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile
0.359Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.8542
Top 49%
0.359DataRank
Top 49%3 citations

Boris Sepesi, Cheuk Hong Leung, Heather Lin, William Nassib William, Annikka Weissferdt +15 more

Papers

Driven by 18 papers — median percentile 51. Top paper: “Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial”.

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

Nature Medicine(2023)10.1038/s41591-022-02128-z
N/A
5.6DataRank · unranked
197 citations

Brian A. Van Tine, Swethajit Biswas, Cheryl McAlpine, Melissa L. Johnson, Anthony J. Olszanski +39 more

Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial

The Lancet(2023)10.1016/s0140-6736(23)01384-3
N/A
5.0DataRank · unranked
230 citations

Steven H. Lin, Wenli Dong, Zhongxing Liao, Saumil Gandhi, Carl M. Gay +23 more

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

Cancer Cell(2022)10.1016/j.ccell.2022.06.006
N/A
3.9DataRank · unranked
106 citations

Jacqulyne Robichaux, Brett W. Carter, Mehmet Altan, Hai T. Tran, Don L. Gibbons +22 more

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

The Lancet Oncology(2022)10.1016/s1470-2045(22)00061-4
N/A
1.5DataRank · unranked
69 citations

Silvia Novello, Alessandra Bearz, Giovanni Luca Ceresoli, Joachim G.J.V. Aerts, James Spicer +22 more

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

New England Journal of Medicine(2015)10.1056/nejmoa1507643
N/A
1.4DataRank · unranked
9414 citations

Luis Paz-Ares, Diane P Holder, David R. Spigel, Martin Steins, Neal E. Ready +38 more

Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial

The Lancet Oncology(2022)10.1016/s1470-2045(22)00508-3
N/A
0.864DataRank · unranked
27 citations

Veronica Puac, Zeena Shelal, Rony Dev, Sandra K. Hanneman, Kristofer Jennings +13 more

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1420
N/A
0.787DataRank · unranked
189 citations

Haniel A. Araújo, Giuseppe Lamberti, Alissa J. Cooper, Neal S. Akhave, Teng Zhou +61 more

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Nature(2024)10.1038/s41586-024-07943-7
N/A
0.769DataRank · unranked
168 citations

Haniel A. Araújo, Minh Truong, Yu Qian, Xin Sun, Ana Galán‐Cobo +95 more

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

Nature Communications(2022)10.1038/s41467-022-29539-3
N/A
0.716DataRank · unranked
117 citations

Yanshuo Chu, Mercy Misoi, María E. Suarez‐Almazor, Jean Tayar, Huifang Lu +33 more

Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer

Cancer(2023)10.1002/cncr.34820
N/A
0.488DataRank · unranked
9 citations

Janet Tu, Denái R. Milton, Bülent Yılmaz, Yanyan Tian, Frank V. Fossella +8 more

A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors

The Oncologist(2023)10.1093/oncolo/oyad158
N/A
0.438DataRank · unranked
10 citations

Apostolia M. Tsimberidou, Xueyao Fu, Siqing Fu, Vivek Subbiah, Anil K. Sood +7 more

Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.8542
Top 49%
0.359DataRank
Top 49%3 citations

Boris Sepesi, Cheuk Hong Leung, Heather Lin, William Nassib William, Annikka Weissferdt +15 more

Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion

The Oncologist(2025)10.1093/oncolo/oyaf413
N/A
0DataRank · unranked
0 citations

Chieh Tseng, Emily Thompson, R. Jason Stafford, Hung Le, Lei Kang +12 more

Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.04.026
N/A
0DataRank · unranked
194 citations

Marcelo V. Negrão, Seyedeh Dibaj, Runzhe Chen, Alexandre Reuben, Jadi M. Bohac +32 more

The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials

Clinical Radiology(2020)10.1016/j.crad.2020.09.024
N/A
0DataRank · unranked
9 citations

Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba, J.J. Lee, Joe Ensor, E.S. Kim +9 more

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC

JTO Clinical and Research Reports(2022)10.1016/j.jtocrr.2022.100391
N/A
0DataRank · unranked
42 citations

Ting Xu, Lirong Wu, Pablo B. Lopez, Clemens Grassberger, Susannah G. Ellsworth +9 more

Alleviating breathlessness in patients with cancer with dexamethasone (ABCD): A parallel-group, double-blind, randomized clinical trial (RCT).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.12112
N/A
0DataRank · unranked
0 citations

Veronica Puac, Zeena Shelal, Rony Dev, Sandra K. Hanneman, Kristofer Jennings +13 more

Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2310
N/A
0DataRank · unranked
21 citations

Alvaro G. Paula, David Molkentine, Laura D. Hover, Monique B. Nilsson, Natalie I. Vokes +17 more